Study S000862

Effect of Liraglutide in Combination With Sulfonylurea (SU) on Glycaemic Control in Subjects With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00395746
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 264
Start: 2006-10
Primary completion: 2007-10
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:sulfonylurea; DRUG:liraglutide
Results posted: TRUE
Secondary identifiers: REGISTRY:JapicCTI-060324

Registered primary outcomes

Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment [after 24 weeks of treatment]

Linked records (7)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023483	Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Jensen TM, Diabetes care	2015	Systematic review	PMID 25504028 DOI	registry reference RESULT:25504028
R0020069	A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Alves C, Diabetes research and clinical practice	2012	Systematic review	PMID 23010561 DOI	registry reference RESULT:23010561
R0022306	The once-daily human glucagon-like peptide-1 analog, liraglutide, improves β-cell function in Japanese patients with type 2 diabetes. Seino Y, Journal of diabetes investigation	2012	Randomized trial	PMID 24843595 DOI	cites ClinicalTrials.gov:NCT00395746; cites JapicCTI:JAPICCTI-060324; registry reference RESULT:24843595
R0017232	Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Buse JB, The Journal of clinical endocrinology and metabolism	2011	Other trial	PMID 21450987 DOI	cites ClinicalTrials.gov:NCT00395746; registry reference DERIVED:21450987
R0020188	GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. Hegedüs L, The Journal of clinical endocrinology and metabolism	2011	Preclinical	PMID 21209033 DOI	cites ClinicalTrials.gov:NCT00395746; registry reference DERIVED:21209033
R0022802	Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial. Seino Y, Journal of diabetes investigation	2011	Randomized trial	PMID 24843499 DOI	cites ClinicalTrials.gov:NCT00395746
R0023279	Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Kaku K, Diabetes, obesity & metabolism	2010	Randomized trial	PMID 20380655 DOI	registry reference RESULT:20380655